Heron Therapeutics, Inc.
HRTX
$0.40
-$0.05-10.74%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 150.71M | 154.90M | 155.10M | 149.69M | 148.52M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 150.71M | 154.90M | 155.10M | 149.69M | 148.52M |
| Cost of Revenue | 56.06M | 53.78M | 52.32M | 50.86M | 53.02M |
| Gross Profit | 94.65M | 101.13M | 102.78M | 98.84M | 95.50M |
| SG&A Expenses | 105.11M | 103.67M | 101.18M | 97.61M | 99.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 161.17M | 157.44M | 153.50M | 148.46M | 152.09M |
| Operating Income | -10.46M | -2.54M | 1.60M | 1.23M | -3.58M |
| Income Before Tax | -30.94M | -20.20M | -13.58M | -931.00K | -7.79M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.94 | -20.20 | -13.58 | -0.93 | -7.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.94M | -20.20M | -13.58M | -931.00K | -7.79M |
| EBIT | -10.46M | -2.54M | 1.60M | 1.23M | -3.58M |
| EBITDA | -8.17M | -224.00K | 3.96M | 3.56M | -1.22M |
| EPS Basic | -0.18 | -0.12 | -0.08 | -0.01 | -0.05 |
| Normalized Basic EPS | -0.07 | -0.03 | 0.00 | 0.00 | -0.02 |
| EPS Diluted | -0.18 | -0.13 | -0.09 | -0.02 | -0.06 |
| Normalized Diluted EPS | -0.07 | -0.03 | 0.00 | 0.00 | -0.03 |
| Average Basic Shares Outstanding | 702.05M | 665.89M | 631.01M | 613.49M | 611.78M |
| Average Diluted Shares Outstanding | 702.05M | 709.32M | 674.44M | 656.92M | 655.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |